Thus, we treated the PLC/PRF/5 and HLE HCC cell lines with the PI3K inhibitor alpelisib, either alone or associated with the Gal‐1 inhibitor OTX008. The gene discussed is HSPG2; the disease is hepatocellular carcinoma.